BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Clinical Outcome
7 results:

  • 1. Functional transcriptomic annotation and protein-protein interaction analysis identify ezh2 and UBE2C as key upregulated proteins in ovarian cancer.
    Martínez-Canales S; López de Rodas M; Nuncia-Cantarero M; Páez R; Amir E; Győrffy B; Pandiella A; Galán-Moya EM; Ocaña A
    Cancer Med; 2018 May; 7(5):1896-1907. PubMed ID: 29575713
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. A crucial epithelial to mesenchymal transition regulator, Sox4/ezh2 axis is closely related to the clinical outcome in pancreatic cancer patients.
    Hasegawa S; Nagano H; Konno M; Eguchi H; Tomokuni A; Tomimaru Y; Asaoka T; Wada H; Hama N; Kawamoto K; Marubashi S; Nishida N; Koseki J; Mori M; Doki Y; Ishii H
    Int J Oncol; 2016 Jan; 48(1):145-52. PubMed ID: 26648239
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. A mathematical model of bimodal epigenetic control of miR-193a in ovarian cancer stem cells.
    Cheng FH; Aguda BD; Tsai JC; Kochańczyk M; Lin JM; Chen GC; Lai HC; Nephew KP; Hwang TW; Chan MW
    PLoS One; 2014; 9(12):e116050. PubMed ID: 25545504
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases ezh2 and SMYD3 in aggressive tumours.
    Sponziello M; Durante C; Boichard A; Dima M; Puppin C; Verrienti A; Tamburrano G; Di Rocco G; Redler A; Lacroix L; Bidart JM; Schlumberger M; Damante G; Russo D; Filetti S
    Mol Cell Endocrinol; 2014 Jul; 392(1-2):8-13. PubMed ID: 24813658
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. A polymorphism in the promoter is associated with ezh2 expression but not with outcome in advanced pancreatic cancer patients.
    Maftouh M; Avan A; Funel N; Paolicchi E; Vasile E; Pacetti P; Vaccaro V; Faviana P; Campani D; Caponi S; Mambrini A; Boggi U; Cantore M; Milella M; Peters GJ; Reni M; Giovannetti E
    Pharmacogenomics; 2014 Apr; 15(5):609-18. PubMed ID: 24798718
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Differentially expressed miRNAs in cancer-stem-like cells: markers for tumor cell aggressiveness of pancreatic cancer.
    Bao B; Ali S; Ahmad A; Li Y; Banerjee S; Kong D; Aboukameel A; Mohammad R; Van Buren E; Azmi AS; Sarkar FH
    Stem Cells Dev; 2014 Aug; 23(16):1947-58. PubMed ID: 24734907
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers.
    Wei Y; Xia W; Zhang Z; Liu J; Wang H; Adsay NV; Albarracin C; Yu D; Abbruzzese JL; Mills GB; Bast RC; Hortobagyi GN; Hung MC
    Mol Carcinog; 2008 Sep; 47(9):701-6. PubMed ID: 18176935
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.